Menu
Menu
Under the Articles of Association, the Company’s Board has three (3) to eight (8) members with no more than two (2) alternates. Board members and alternates are elected at the AGM. The Board’s assignment is valid until the end of the next AGM. Management and all Board members can be reached through the Company’s headquarters at Mårtenstorget 5, SE-223 51 Lund, Sweden. The Board’s work is governed by the Companies Act, the Articles of Association and the Rules of Procedure adopted by the Board.
Number of shares: 32 822
Number of warrants: 0
Independent of the company’s major shareholders, the company, and its management.
Kerstin Jakobsson has extensive experience in board work and leading executive positions in international business development, marketing, and sales for life science companies, in medical technology and diagnostics. Kerstin has been CEO of Kongsberg Beam Technology AS, Ortoma AB and Medicon Village Innovation AB.
Education: Master of Science in chemistry at Lund’s University. EFL’s board education, and trained at the Board Academy.
Other current positions: Chairman of the Diagonal Bio AB (publ.). Board member of Queen Invest AB, OctaQuest AB, TeEkMi (Sustainability) Holding AB, NanoLund at Lund’s University and Stiftelsen TEM.
Number of shares: 120 000
Number of warrants: 0
Independent of the company, dependent of larger shareholders.
Ulf Bladin has previously held positions such as General Manager, Vice President for the EMEA region at Hycor Biomedical, Vice President of Commercial Operations Europe at Thermo Fisher Scientific Immuno Diagnostics Division, and Vice President with global responsibility for Marketing, Health Economy, Corporate Communications, Scientific & Regulatory Affairs at Phadia AB. Ulf Bladin has also held senior commercial positions in the pharmaceutical industry at Pfizer and Merck Sharp & Dhome.
Education: Bachelor of Medicine, Karolinska Institutet, Bachelor of Business Administration and Master’s degree, Stockholm School of Economics.
Other current positions: CEO and board member of Prolight Diagnostics AB (publ.), SPCIN AB, and UB Management Invest AB.
Number of shares: 2 100 000
Number of warrants: 0
Dependent of the company, independent of larger shareholders.
Professor of Physics at Lund University until 2016. Since 2016, Director of Biophotonics (leading a team of 40 researchers) at Tyndall National Institute, Ireland. Received the Erna Ebeling Prize from the Swedish Society for Medical Engineering and Physics in 2003. Pre-candidate for the appointment of the professorship in Biomedical Physics at the Royal Institute of Technology, Stockholm, in 1996. Co-author of over 200 articles in peer-reviewed journals.
Other current positions: Director of Biophotonics at Tyndall National Institute, Ireland. Deputy Director of the Photonics Centre IPIC, Cork, Ireland. Professor of Physics at University College Cork, Ireland.
Number of shares: 410 000
Number of warrants: 1 000 000
Independent of the company’s major shareholders, dependent on the company and its management.
Mattias Lundin has extensive experience driving growth globally with intelligent and new technology and is an international leader with 18 years of experience in the healthcare industry. He most recently came from a position as Global Sales Manager for the Swedish, world-leading medical technology company CellaVision. He has also worked as Nordic CEO, CEO of the Netherlands and VP of Commercial mature markets at ArjoHuntleigh (now Arjo) within the Getinge Group.
Education: Degree Certificate in Marketing Management at IHM Business School, Stockholm.
Other current positions: Chairman of the Board and CEO of Decon Products Holding AB. Board member of Neola Medical AB.
Number of shares: 840 000
Number of warrants: 230 000
Independent of the company’s major shareholders, the company, and its management.
Marcus Åström has over 20 years of experience in the financial industry, where he has worked globally with institutional distribution and business development. He has experience from several leading positions, including at East Capital, as responsible for business relations with leading institutions in several markets, including the Nordics and the Middle East.
Education: Master of Business Administration from Umeå University.
Other current positions: Active in his own company, Riverstream Partners, where he assists companies with, among other things, developing strategies and identifying the right partners for the company’s growth plans.
Number of shares: 100 269
Number of warrants: 0
Education: PhD in Analytical Chemistry, Uppsala University.
Background: Sanna Wallenborg has extensive international experience in life sciences, medical technology, and diagnostic products (IVD). She has held leadership roles in both global companies and start-ups, most recently serving as Vice President & General Manager of the Radiometer Immunoassay Business Unit at Radiometer (part of the Danaher Corporation). At Radiometer, she was also responsible for Clinical and Medical Affairs.
Other current positions: –
Number of shares: 230 125
Number of warrants: 0
Education: Bachelor in Business Administration and Economics, Lund University.
Background: Henrik Ljung has a background as a certified auditor and extensive experience as a CFO, including positions at Cerdo Bankpartner Aktiebolag, Acconeer AB, Ballingslöv AB, AB Sardus, and Malmöhus Invest AB.
Other current positions: CFO of SpectraCure AB, Prolight Diagnostics AB, NanoEcho AB, and Carbiotix AB. Board member of Ljung och Winbladh AB.
Number of shares: 167 500
Number of warrants: 0
Education: Master’s degree in Mechanical Engineering, Lund University.
Background: Lars Lindgren has 35 years of experience and extensive expertise in the development of medical equipment, working in both startups and multinational companies as a Project Manager and Director of Research & Development.
Number of shares: 109 707
Number of warrants: 0
Education: Master of Science in Electrical Engineering, Lund University.
Background: Andreas Johansson has over 20 years of experience in product development and system design, encompassing both hardware and software. His previous work includes algorithm development for handwriting recognition, consultancy in embedded systems, and most recently, serving as a systems engineer at Flatfrog AB.
Number of shares: 0
Number of warrants: 0
Education: Master of Science in Chemical Engineering, Lund University.
Background: Anna Linde has over 20 years of experience in quality management systems, project management, and technical product management for medical devices and in vitro diagnostics in the industry. She has worked with products from the research phase, through the design/development and launch phase, to product maintenance in both startups and international companies. She has previously worked for BrainCool, Immunovia, Baxter, and Gambro.
Number of shares: 914
Number of warrants: 0
Education: Executive MBA, Copenhagen Business School.
Background: Anders Wallseth has extensive international experience in commercialising medical technology and diagnostic products (IVD). He has held leadership roles in global companies and start-ups as an employee, board member, and consultant. Most recently, he came from HemoCue, where he served as Senior Director of International Sales.
Other current positions: Own consulting business through Wallseth Consulting AB. Board member of Starfish of Sweden AB and Enersize AB.
The Nomination Committee for the 2025 Annual General Meeting of Lumito AB (publ) consists of the following individuals:
The primary task of the Nomination Committee is to present proposals for board members and board remuneration. Additionally, the Nomination Committee will propose an auditor, a chair for the meeting, and, if deemed necessary, changes to the instructions for the Nomination Committee.
Shareholders who wish to submit proposals to the Nomination Committee can do so by email to: valberedning@lumito.se,
or in writing to the following address:
Lumito AB
Att: Valberedning
Mårtenstorget 5
223 51 Lund
Sweden
Proposals must be received by the Nomination Committee no later than February 28, 2025.
The Nomination Committee’s proposals will be presented well in advance of the Annual General Meeting and will be published on the company’s website in connection with this.
The Annual General Meeting will be held on Tuesday, May 8, 2025, at Lumito’s office at Mårtenstorget 5, Lund.
Articles of association
We have telephone hours on weekdays between 08:00 and 14:30. Closed for lunch 12-13.
Phone: +46(0)10-204 00 15
Mail: info@lumito.se
Lumito AB (publ)
Mårtenstorget 5, 223 51, Lund